12:00 CET

Presentation of the Q1 2021 results

Oncopeptides AB will publish its report for the first quarter 2021 on May 26. Investors, financial analysts and media are invited to participate in a webcast with a QnA session on the same day at 12:00 CEST. The event will be hosted by CEO, Marty J Duvall and members of the Oncopeptides’ Leadership team. The presentation will be held in English.

The webcast will be streamed via this link.

Phone numbers for participants from:

Sweden: +46 8 566 427 05

Europe: +44 3333 009 268

USA: +1 833 823 05 89

Upcoming events

Silent Period

-

FDA - Oncologic Drugs Advisory Committee (ODAC) Meeting

The US Food and Drug Administration, FDA, has announced a forthcoming public advisory committee meeting of the Oncologic Drugs Advisory Committee (ODAC), on October 28, 2021 concerning Oncopeptides’ product Pepaxto. The information is in line with the FDA safety alert on July 28, where the FDA stated that a public meeting may be hold to discuss the safety findings from the OCEAN study.

Interim Report Q3 2021

08:00 CET

Silent Period

-

Year-end report 2021

08:00 CET

Silent Period

-

Silent Period

-